Acurx Pharmaceuticals logo

Acurx PharmaceuticalsNASDAQ: ACXP

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

25 June 2021

Next earnings report:

13 November 2024

Last dividends:

N/A

Next dividends:

N/A
$31.52 M
-61%vs. 3y high
29%vs. sector
-vs. 3y high
-vs. sector
-56%vs. 3y high
91%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Wed, 30 Oct 2024 20:52:20 GMT
$1.94$0.00(0.00%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

ACXP Latest News

Acurx Announces New Bile Acid and Microbiome Analyses from Ph2b Trial of Ibezapolstat in CDI Patients Presented at IDWeek Scientific Conference
prnewswire.com21 October 2024 Sentiment: POSITIVE

The data presented indicate a favorable gut bile acid profile which may contribute to ibezapostat's beneficial anti-recurrence effect in patients with C. difficile Infection (CDI) Ibezapolstat treatment of patients with CDI is associated with the restoration of beneficial bacterial classes in the gut Preparation continues to advance ibezapolstat into international Phase 3 clinical trials for treatment of C.

Acurx Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 13, 2024
prnewswire.com16 October 2024 Sentiment: POSITIVE

STATEN ISLAND, N.Y. , Oct. 16, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late- stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its third quarter 2024 financial results on Wednesday, November 13, 2024 at 8:00 am ET before the U.S. financial markets open.

New to the Street Resigns Acurx Pharmaceuticals, Inc. to Multi-Platform Media Series Featuring Broadcast Television, Earned Media, and Outdoor Advertising Support
accesswire.com14 October 2024 Sentiment: POSITIVE

The new series features continued broadcast television interviews, earned media placements, and a comprehensive outdoor advertising campaign. NEW YORK, NY / ACCESSWIRE / October 14, 2024 / New to The Street, one of the leading U.S. business television platforms, is pleased to announce the renewal of its media partnership with Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP), a late-stage biopharmaceutical company.

Acurx Pharmaceuticals, Inc. Reports Second Quarter 2024 Results and Provides Business Update
prnewswire.com09 August 2024 Sentiment: POSITIVE

STATEN ISLAND, N.Y. , Aug. 9, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the second quarter ended June 30, 2024.

Acurx Pharmaceuticals, Inc. (ACXP) Q4 2023 Earnings Call Transcript
Seeking Alpha18 March 2024 Sentiment: POSITIVE

Acurx Pharmaceuticals, Inc. (ACXP) Q4 2023 Earnings Call Transcript

Acurx Pharmaceuticals, Inc. to Discuss Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024 Conference Call and Provide Business Update
PRNewsWire04 March 2024 Sentiment: NEGATIVE

STATEN ISLAND, N.Y. , March 4, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will release its fourth quarter and full year 2023 financial results on Monday, March 18, 2024, at 8:00 am ET before the U.S. financial markets open.

Acurx Pharmaceuticals to Present at the Microcap Conference, January 31, 2024 - February 1, 2024
PRNewsWire23 January 2024 Sentiment: POSITIVE

STATEN ISLAND, N.Y. , Jan. 23, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. ("Acurx" or the "Company") (NASDAQ: "ACXP"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, today announced that David P.

Acurx Sell-Off Presents Opportunity Before Upcoming Data Release
Seeking Alpha22 January 2024 Sentiment: POSITIVE

Acurx shares opened ~25% lower on Jan 17th, after releasing positive data suggesting its C. diff antibiotic outperformed standard treatment in restoring the gut microbiome. The decline in share price since then may be due to misaligned investor expectations regarding the release of sustained clinical cure rates. Acurx is expected to release additional data, including 94-day sustained clinical cure rates, which could further establish its antibiotic as a preferred treatment for C. diff.

What type of business is Acurx Pharmaceuticals?

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

What sector is Acurx Pharmaceuticals in?

Acurx Pharmaceuticals is in the Healthcare sector

What industry is Acurx Pharmaceuticals in?

Acurx Pharmaceuticals is in the Biotechnology industry

What country is Acurx Pharmaceuticals from?

Acurx Pharmaceuticals is headquartered in United States

When did Acurx Pharmaceuticals go public?

Acurx Pharmaceuticals initial public offering (IPO) was on 25 June 2021

What is Acurx Pharmaceuticals website?

https://www.acurxpharma.com

Is Acurx Pharmaceuticals in the S&P 500?

No, Acurx Pharmaceuticals is not included in the S&P 500 index

Is Acurx Pharmaceuticals in the NASDAQ 100?

No, Acurx Pharmaceuticals is not included in the NASDAQ 100 index

Is Acurx Pharmaceuticals in the Dow Jones?

No, Acurx Pharmaceuticals is not included in the Dow Jones index

When was Acurx Pharmaceuticals the previous earnings report?

No data

When does Acurx Pharmaceuticals earnings report?

The next expected earnings date for Acurx Pharmaceuticals is 13 November 2024